Aclaris Therapeutics (ACRS) Tops Q2 EPS by 1c

Aclaris Therapeutics (NASDAQ: ACRS) reported Q2 EPS of ($0.13), $0.01 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.77 million versus the consensus estimate of $1.28 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Mizuho Starts Sol Gel Technologies Ltd. (SLGL) at Outperform
• The Trade Desk (TTD) Reiterated at Market Perform by Citizens Amid Bad News